

WHEN RELAPSED OR REFRACTORY *NPM1*-m AML MEETS KOMZIFTI™

THIS IS WHERE RESILIENCE MAY HAPPEN

If your doctor has determined other treatment options are not appropriate for you, **there's a once daily targeted treatment to consider.**

What is KOMZIFTI?

KOMZIFTI is a prescription medicine used to treat adults with acute myeloid leukemia (AML) with a nucleophosmin 1 (*NPM1*) mutation whose AML has come back or did not improve after previous treatment(s) and who have no other satisfactory treatment options.

Your healthcare provider will perform a test to make sure that KOMZIFTI is right for you.

It is not known if KOMZIFTI is safe and effective in children.

Important Safety Information

What is the most important information I should know about KOMZIFTI?

KOMZIFTI can cause serious side effects including:

Differentiation Syndrome: Differentiation syndrome is a condition that affects your blood cells that is common during treatment with KOMZIFTI and can be life-threatening or lead to death if not treated. Differentiation syndrome can happen as early as 3 days after you start KOMZIFTI treatment and can also happen later during treatment with KOMZIFTI. Tell your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following signs or symptoms of differentiation syndrome during treatment with KOMZIFTI:

- fever
- joint or bone pain
- dizziness
- shortness of breath or trouble breathing
- cough
- chest pain
- rapid weight gain
- rash
- decreased urine output
- swelling of hands, feet, ankles, or legs

Please see Important Safety Information on pages 8–9 and full Prescribing Information, including **Boxed WARNING**, and Medication Guide for additional information.



Actor portrayal.

 **komzifti**[™]
(ziftomenib)
200 mg capsules

Knowing your *NPM1*-mutation status is the first step

There are many types of AML



NPM1-mutated AML is a specific type of AML

Understanding your specific AML type can help you understand the treatments your doctor may prescribe for you. In *NPM1*-mutated AML, certain genetic mutations (a change in your DNA) cause cancer cells to form. In recent years, scientists have developed different treatments that target specific mutations.

You may also hear the terms **relapsed** (AML has come back) or **refractory** (AML has not improved after treatment).



How do I know if I have *NPM1*-mutated AML?

Your doctor will order tests to find out if you have *NPM1*-mutated AML. You can have more than one mutation at a time. Knowing the specific mutation(s) helps your doctor determine the right treatment(s) for you.

NPM1-mutated AML is the most common type of AML.

Important Safety Information (cont'd)

Differentiation Syndrome (cont'd)


If you develop signs and symptoms of differentiation syndrome during treatment with KOMZIFTI, your healthcare provider may temporarily stop KOMZIFTI and give you a corticosteroid medicine. Your healthcare provider will monitor you until your signs and symptoms improve.

Changes in electrical activity of your heart (QT prolongation). Changes in the electrical activity of your heart may lead to irregular heartbeats (rhythm) that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with KOMZIFTI. Tell your healthcare provider right away if you feel faint, lightheaded, or dizzy, or if you have shortness of breath, or if you feel your heart beating irregularly or fast during treatment with KOMZIFTI.

How does KOMZIFTI work?

KOMZIFTI works differently from chemotherapy

KOMZIFTI is a targeted therapy that specifically targets menin (also known as a menin inhibitor) and can lead to the development of normal blood cells



If your doctor has determined other treatment options are not appropriate for you, **KOMZIFTI could be your next step.**

Please see Important Safety Information on pages 8–9 and [full Prescribing Information](#), including **Boxed WARNING**, and [Medication Guide](#) for additional information.



Can KOMZIFTI be your next step?

Ask your doctor

If you have relapsed or refractory *NPM1*-mutated AML, your doctor will determine if KOMZIFTI is right for you and what you can expect from treatment.

How was KOMZIFTI evaluated in a clinical study?

The **largest** study leading to an approval of a menin inhibitor in adults with R/R *NPM1*-m AML



The median age was 69 years (range: 22-86 years). 38% of patients were <65 years of age. 63% of patients were ≥65 years of age.

How were the patients assessed for response?

The primary goal (or primary endpoint) of the study was to see how many patients who received KOMZIFTI achieved complete remission (CR) or complete remission with partial hematologic recovery (CRh).

Complete remission

No signs of leukemia and blood counts returned to normal

Complete remission with partial hematologic recovery

No signs of leukemia, but some blood counts did not return to normal


The study also looked at other important outcomes, including how long it took for the treatment to start working and whether patients needed blood transfusions, as well as drug safety and tolerability.

Important Safety Information (cont'd)

Before taking KOMZIFTI, tell your healthcare provider about all of your medical conditions, including if you:

- have any heart problems, including a condition called long QT syndrome.
- have problems with abnormal levels of salts in your blood (electrolytes), such as potassium and magnesium levels.
- are pregnant or plan to become pregnant. KOMZIFTI can harm your unborn baby.

Results seen in the clinical study



Important Safety Information (cont'd)

- **Females who are able to become pregnant:**
 - Your healthcare provider will perform a pregnancy test before you start treatment with KOMZIFTI.
 - Use effective birth control (contraception) during treatment with KOMZIFTI and for 6 months after
- **Males who have female partners who are able to become pregnant:**
 - Use effective birth control (contraception) during treatment with KOMZIFTI and for 3 months after the last dose.
 - Talk to your healthcare provider about birth control methods you can use during this time.
- are breastfeeding or plan to breastfeed. It is not known if KOMZIFTI passes into your breast milk. Do not breastfeed during your treatment with KOMZIFTI and for 2 weeks after your last dose.

Please see Important Safety Information on pages 8-9 and [full Prescribing Information](#), including **Boxed WARNING**, and [Medication Guide](#) for additional information.



KOMZIFTI is the only FDA-approved menin inhibitor that offers once daily dosing

Convenient once daily oral dosing


Consider how KOMZIFTI could fit into your daily routine

Swallow 3 capsules
(total 600 mg)
once a day



Do not break, open, or chew the capsules.

On an empty stomach



Take KOMZIFTI at least 1 hour before or 2 hours after a meal

Around the same time each day



If you miss a dose or did not take it at your regularly scheduled time

- Take the dose as soon as you remember and at least 12 hours prior to your next scheduled dose
- Then return to your normal schedule the next day
- Do not take 2 doses within 12 hours of each other to make up for the missed dose

Important Safety Information (cont'd)

Tell your healthcare provider about any other medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

KOMZIFTI and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist.

If you take medicine to reduce stomach acid:

- Avoid taking a proton pump inhibitor (PPI) medicine with KOMZIFTI.
- Take KOMZIFTI either 2 hours before or 10 hours after taking an H2 receptor blocker medicine.
- Take KOMZIFTI either 2 hours before or 2 hours after taking a locally acting antacid medicine (such as calcium carbonate).


Storing KOMZIFTI does not require special steps



Store KOMZIFTI at room temperature between 68°F to 77°F (20°C to 25°C).



KOMZIFTI comes in a container with a child-resistant cap.



Keep KOMZIFTI and all medicines out of the reach of children.

Be sure to follow your doctor's instructions exactly on how to take KOMZIFTI.

It's normal to wonder if your treatment is working. Your doctor may keep you on KOMZIFTI for at least 6 months to allow time for your treatment to work, unless your disease progresses or you experience unacceptable side effects.

Do not change your dose or stop taking KOMZIFTI without talking to your healthcare provider.

AML, acute myeloid leukemia; CR, complete remission; CRh, complete remission with partial hematologic recovery; DNA, deoxyribonucleic acid; *NPM1*, nucleophosmin 1; *NPM1-m*, mutated nucleophosmin 1; R/R, relapsed or refractory.

Tips to help you remember to take KOMZIFTI

- Consider setting a daily alarm with a label that reads "Take KOMZIFTI"
- Pair taking KOMZIFTI with a daily routine, like brushing your teeth
- Ensure that the daily routine allows you to take KOMZIFTI on an empty stomach
- If you live with someone, tell them you're taking KOMZIFTI and that it's important you take it around the same time daily
- Place a calendar in a visible spot, and cross off each day after you've taken your medication

Please see Important Safety Information on pages 8–9 and [full Prescribing Information](#), including **Boxed WARNING**, and [Medication Guide](#) for additional information.

 **komzifti**[™]
(ziftomenib)
200 mg capsules

Talk with your healthcare team about possible side effects

KOMZIFTI can cause differentiation syndrome

Differentiation syndrome is a serious condition that affects your blood cells and can be life-threatening or lead to death if not treated. Differentiation syndrome can happen as early as 3 days after you start KOMZIFTI treatment and can also happen later during treatment with KOMZIFTI.



Tell your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following signs or symptoms of differentiation syndrome during treatment with KOMZIFTI:

Symptoms of differentiation syndrome

- Fever
- Joint or bone pain
- Dizziness
- Shortness of breath or trouble breathing
- Cough
- Chest pain
- Rapid weight gain
- Rash
- Decreased urine output
- Swelling of hands, feet, ankles, or legs

If you develop differentiation syndrome during treatment, your healthcare provider may temporarily stop KOMZIFTI and give you a corticosteroid medicine. Your healthcare provider will monitor you until you improve.

KOMZIFTI can cause QT prolongation.

Changes in the electrical activity of your heart (QT prolongation) may lead to irregular heartbeats (rhythm) that can be life-threatening or lead to death. Your healthcare provider will check the electrical activity of your heart with a test called an electrocardiogram (ECG) and will also do blood tests to check your potassium and magnesium levels before and during treatment with KOMZIFTI. Tell your healthcare provider right away if you feel faint, lightheaded, or dizzy, or if you have shortness of breath, or if you feel your heart beating irregularly or fast during treatment with KOMZIFTI.

Most common side effects of KOMZIFTI



- Infections, including bacterial infections
- Bleeding
- Diarrhea
- Nausea
- Feeling tired
- Swelling in the arms and legs
- Muscle, bone, and joint pain
- Itching
- Fever with decreased white blood cell counts
- Changes in liver function tests

Your healthcare provider may decrease your dose, temporarily stop, or completely stop your treatment with KOMZIFTI if you develop certain side effects during treatment with KOMZIFTI.

KOMZIFTI may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.

These are not all of the possible side effects of KOMZIFTI.

Call your doctor for medical advice about side effects. **You are encouraged to report side effects of prescription drugs to FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.**

Treatment affects each person differently. If you think you're experiencing a side effect from your treatment, reach out to your doctor right away.

Before taking KOMZIFTI, tell your healthcare provider about all your medical conditions, including if you:

- have any heart problems, including a condition called long QT syndrome
- have problems with abnormal levels of salts in your blood (electrolytes), such as potassium and magnesium levels
- are pregnant or plan to become pregnant. KOMZIFTI can harm your unborn baby.

• Females who are able to become pregnant:

- Your healthcare provider will perform a pregnancy test before you start treatment with KOMZIFTI
- Use effective birth control (contraception) during treatment with KOMZIFTI and for 6 months after the last dose

• Males who have female partners who are able to become pregnant:

- Use effective birth control (contraception) during treatment with KOMZIFTI and for 3 months after the last dose
- Talk to your healthcare provider about birth control methods you can use during this time

- Are breastfeeding or plan to breastfeed. It is not known if KOMZIFTI passes into your breast milk. Do not breastfeed during your treatment with KOMZIFTI and for 2 weeks after your last dose

Tell your healthcare provider about any other medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

KOMZIFTI and other medicines may affect each other causing side effects.


Please see Important Safety Information on pages 8-9 and [full Prescribing Information](#), including **Boxed WARNING**, and [Medication Guide](#) for additional information.



Get started with your treatment today

We're here for you

Pay as little as \$0 with the KOMZIFTI Copay Card



Eligible commercially insured patients may utilize KOMZIFTI Copay Support and **pay as little as \$0**. Ask the pharmacist for details.

Our goal is to help you get your medicine as quickly and easily as possible



With **Kura RxKconnect™**, you won't need to figure out insurance coverage on your own. We can help you move through your journey with confidence.

Join **Kura RxKconnect™** for support

Want more information?

Call us at 1-844-587-2777
Monday – Friday, 8 AM – 8 PM ET

Advocacy organizations that offer support and educational resources for patients with AML and their families^a

Blood Cancer United

bloodcancerunited.org

- Offers a wide variety of resources for patients that can help them learn about AML and navigate their journey
- Includes materials for both patients and care partners



powerfulpatients.org

- Organization focused on empowering people with cancer
- Features an AML-specific hub that connects individuals with peer mentors who offer personalized guidance

HealthTree Foundation

healthtree.org

- Offers comprehensive patient education resources to help patients understand their disease
- Provides a robust community platform where patients with AML and care partners can connect

KNOW AML

know-aml.com

- A global education and awareness initiative that hosts an online collection of downloadable resources



thepatientstory.com

- Organization that shares real patient and survivor stories to help people better understand cancer diagnoses, treatments, side effects, and life beyond cancer
- Provides trusted resources through interviews, podcasts, and medically reviewed content to support patients and care partners



cancercares.org

- Connect with oncology social workers to help you navigate the emotional and day-to-day challenges that come with life with AML
- Find support groups

^aThe organizations listed above are independent from Kura Oncology and Kyowa Kirin, and this list is subject to change. This information is provided as a resource for patients and is not an endorsement or guarantee of assistance, nor is it meant to replace the advice of a healthcare provider.

Please see Important Safety Information on pages 8-9 and [full Prescribing Information](#), including **Boxed WARNING**, and [Medication Guide](#) for additional information.



komziftiTM
(ziftomenib)
200 mg capsules

Is **KOMZIFTI** right for you?
Talk to your doctor.

Explore additional information
and resources at [komzifti.com](https://www.komzifti.com)

Please see Important Safety Information on pages 8–9 and [full Prescribing Information](#), including **Boxed WARNING**, and [Medication Guide](#) for additional information.